DIGITAL HEALTHCARE

Revibe Technologies Announces Clinical Development Updates for its Investigational FokusRx Prescription Digital Therapy for the Treatment of ADHD

Revibe technologies | February 09, 2022

Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining the efficacy of FokusRx in school aged children with attention deficit hyperactivity disorder (ADHD). FokusRx is an investigational SaMD (Software as a Medical Device) that has the potential to provide a new nonpharmacologic approach to treating attention, focus and hyperactivity deficits associated with ADHD, and other mental health conditions.

ADHD is one of the most commonly diagnosed and increasingly prevalent mental health disorders in children and adolescents. In the United States, 6.1 million children aged 2-17 years have been diagnosed with ADHD. Approximately 50% of families stop using prescription drug treatments for ADHD within a year. Over 30% of parents refuse pharmacologic treatment for their children with ADHD.

In this, single-arm multi-rater feasibility study, parents (n = 38) and teachers (n = 26) rated youth aged 8-12 years with a parent-reported diagnosis of ADHD. Youth were attending in-person classroom learning and not taking medication for their ADHD. The study included a number of outcome measures including the ADHD-RS-5 (Home and School versions), Conners 4 – short version, Weiss Functional Impairment Rating Scale-Parent Form (WFIRS-P), and the Academic Performance Rating Scale (APRS). To be included in the analyses, youth had to have worn the Revibe Connect wearable device to school Monday to Friday for a at least three days per week or a minimum of 15 days total for a period of four weeks.

"We are pleased that the feasibility study has proven to be a successful exercise that de-risks our upcoming randomized sham-controlled pivotal trial. The moderate to large effect sizes observed and change scores that exceed standards for minimally important (clinically significant) differences, provide encouraging preliminary evidence supporting the efficacy of our intervention", says Dr. Lindsay Ayearst, Chief Scientific Officer of Revibe.

Revibe's Scientific and Medical Advisory Board member, Dr. Margaret Weiss, Director of Clinical Research in Child Psychiatry at Cambridge Health Alliance, stated, "These results are consistent across both symptoms and functioning, and across informants. They would translate into clinically significant change. Most impressive is the demonstration of an effect on academic performance."

"The data from the classroom feasibility study suggests FokusRx can effectively and safely improve ADHD symptoms and functioning in school-aged children. It is our intention that FokusRx will provide kids and parents another option to help them succeed and reach their full potential. We are excited to begin designing our pivotal trial planned for the fall."

Joseph Koziak, Chief Executive Officer of Revibe

About FokusRx
FokusRx is an investigational SaMD designed to provide a new nonpharmacologic approach to treating symptoms and impairment associated with ADHD. The FokusRx software is embedded within a dedicated smart watch to act as a digital therapeutic wearable.

About Revibe Technologies
Revibe Technologies is passionate about leveraging technology to help children and adults with focus and attention problems overcome obstacles in order to succeed in life. Revibe Technologies hopes to be a resource for students, parents, teachers, schools, and clinicians.

Spotlight

Katrina Gore, Director, Pfizer Research Statistics & Joint winner of the 2015 RSS / PSI prize for statistical excellence in the pharmaceutical industry. It is unusual to pick up a recent issue of Nature or Science that doesn’t include an article on the issue of non-reproducible research. It would seem that research is plagued by findings that are not reliable and cannot be reproduced. The pharmaceutical industry is not immune to these same issues. Replication of published research findings is a key component of drug target identification and provides confidence to progress internal drug projects. Additionally, we use data from internal assays to assess the biological and pharmacokinetic activity, selectivity and safety of novel compounds, and to make decisions that impact their progression towards clinical development.

Spotlight

Katrina Gore, Director, Pfizer Research Statistics & Joint winner of the 2015 RSS / PSI prize for statistical excellence in the pharmaceutical industry. It is unusual to pick up a recent issue of Nature or Science that doesn’t include an article on the issue of non-reproducible research. It would seem that research is plagued by findings that are not reliable and cannot be reproduced. The pharmaceutical industry is not immune to these same issues. Replication of published research findings is a key component of drug target identification and provides confidence to progress internal drug projects. Additionally, we use data from internal assays to assess the biological and pharmacokinetic activity, selectivity and safety of novel compounds, and to make decisions that impact their progression towards clinical development.

Related News

HEALTH TECHNOLOGY

Homerton Healthcare Chooses Sectra as its Enterprise Imaging Cloud Partner

Homerton Healthcare | June 14, 2022

Medical imaging technology and cybersecurity provider, Sectra, announced that it has been chosen by Homerton Healthcare NHS Foundation Trust to offer its fully cloud-based enterprise imaging solution. Following the announcement, Sectra will be responsible for the hardware, software, and other aspects of IT for Homerton Healthcare. "Having our new imaging solution as a fully managed cloud service will allow us to shift the focus of our IT staff. Our team will be relieved of IT management responsibilities, which will be a significant benefit. We also expect to see clinical benefits, such as faster access to new features and new technology. Moving to a scalable cloud solution furthers our ambitions for a consolidated cloud system supporting all hospitals in our ICS (Integrated Care System) and is a vital first step towards realizing our collaboration potential in the north eastLondon. -Niall Canavan, Homerton Director of IT and Systems Homerton Healthcare NHS Foundation Trust is a trusted provider of health services for communities in Hackney and surrounding London boroughs. The contract will enable Homerton Healthcare to make the most of Sectra’s cloud service for enterprise imaging. "Sectra and Microsoft share a dedication to improving healthcare and provide high availability, performance and security. I am excited to leverage our experience of providing enterprise imaging in regional and collaborative settings to help Homerton Healthcare achieve clinical benefits, share workloads, and provide their clinicians with modern tools." - Jane Rendall, Managing Director at Sectra, UK andIreland.

Read More

HEALTH TECHNOLOGY

Francisco Partners Launches Data Company Merative After Acquiring IBM’s Healthcare Data and Analytics Assets

Francisco Partners and Merative | July 01, 2022

The acquisition of the healthcare data and analytics assets that were a part of IBM's Watson Health business, has been completed, according to Francisco Partners, a renowned international investment firm that specializes in working with technology companies. The new standalone business, which will be owned by Francisco Partners, will be known as Merative and have its headquarters in Ann Arbor, Michigan. Merative serves clients in the life sciences, provider, imaging, health plan, employer, and government health and human services sectors by bringing together market-leading offerings that give value across the global healthcare ecosystem. “Merative has market leading products, top clients and talented leadership. With the commitment, support and deep experience of Francisco Partners, we will invest heavily in expanding the reach of these products as we continue to work with clients to improve healthcare delivery, decision making and performance.” Gerry McCarthy Paul Roma, General Manager of the Watson Health business, is slated to transition to the role of Senior Advisor to Francisco Partners. “Paul has been instrumental in driving crucial transformation of the business. His relentless focus on customers has laid a solid foundation to build on, and we thank him for his leadership,” said McCarthy.

Read More

MEDICAL DEVICES

Priority Health announces launch of new health navigation solution, PriorityGPS™

Priority Health | July 21, 2022

Priority Health, a nationally recognized nonprofit health plan, announced today the launch of PriorityGPS™, an integrated health navigation and advocacy solution. PriorityGPS will be delivered through a strategic partnership with Accolade a Personalized Healthcare service, and is available for self-funded large employers. According to a survey conducted by the International Federation of Employee Benefit Plans, about half of employees don’t understand their benefits. PriorityGPS is designed to alleviate the stress human resources professionals face as the go-between with employees and their benefits carriers by providing direct 1:1 help for employees. Through one point of contact, employees have access to appointment scheduling, benefits and coverage guidance, and various virtual care providers among several other benefits. While advocacy services are available in the ASO employer group market, they are often offered as a standalone or “carved out” service. This solution offers the highest level of employee support, providing all employees a high-touch, relational experience with a care support team available 24/7 though phone, web or mobile app. “Priority Health always strives to bring new opportunities to employers wanting to meet the needs of their employees and their health goals. Partnering with Accolade to create PriorityGPS is a great example of that kind of valued collaboration. This new product was designed with convenience and accessibility in mind, both for employers and employees, while continuing to provide the same high-quality care Priority Health is known for.” Megan Schmidt, senior vice president of employer solutions at Priority Health Announced earlier this year, the strategic partnership between Priority Health and Accolade brings together virtual care services and personalized navigation capabilities to enable innovative solutions, like PriorityGPS, with a comprehensive support model for Priority Health members. “We are excited to collaborate with Priority Health to offer a unique solution in Michigan to meet the needs of employers throughout the state,” said Kristin Herrera, executive vice president and general manager for health plan and enterprise channel at Accolade. “Our partnership and innovative approach bring simplicity to a complex healthcare system. By proactively connecting and staying with members throughout their health journey, we deliver on affordability, improved outcomes and provide an exceptional member experience. Our solution goes beyond delivering transactional care to caring for the whole person. We support physical and mental health by building trusting relationships and leveraging real time data to improve employee engagement and job satisfaction while lowering costs for Michigan employers.” About Priority Health With over 30 years in business, Priority Health is the second largest health plan in Michigan, offering an extensive portfolio of health benefits options for employer groups and individuals, including Medicare and Medicaid plans. Serving more than one million members each year and offering a broad network of primary care physicians in Michigan, Priority Health continues to be recognized as a leader for quality, customer service, transparency and product innovation. About Accolade, Inc Accolade provides millions of people and their families with an exceptional healthcare experience that is personal, data driven and value based to help every person live their healthiest life. Accolade solutions combine virtual primary care, mental health support and expert medical opinion services with intelligent technology and best-in-class care navigation. Accolade’s Personalized Healthcare approach puts humanity back in healthcare by building relationships that connect people and their families to the right care at the right time to improve outcomes, lower costs and deliver consumer satisfaction. Accolade consistently receives consumer satisfaction ratings over 90%.

Read More